Compare
Boston Scientific Corp vs Becton Dickinson & Co vs Stryker Corp vs Medline Inc.
| Latest fiscal year | Boston Scientific Corp BSX | Becton Dickinson & Co BDX | Stryker Corp SYK | Medline Inc. MDLN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $20.07B | $21.84B | $25.12B | $28.43B |
| Revenue growth (YoY) | +19.9% | +8.2% | +11.2% | +11.5% |
| Gross margin | 69.0% | 45.4% (computed) | 64.0% | 26.4% |
| Operating margin | 18.0% | 11.8% | 19.5% | 7.8% |
| Net margin | 14.4% | 7.7% | 12.9% | 4.1% |
| Net income | $2.89B | $1.68B | $3.25B | $1.16B |
| EPS (Diluted) | $1.94 | $5.82 | $8.40 | -$0.01 |
| Operating cash flow | $4.53B | $3.43B | $5.04B | $1.74B |
| Free cash flow | $3.66B | $2.67B | $4.28B | $1.30B |
| Cash & equivalents | $1.97B | $641.00M | $4.01B | $1.94B |
| Total assets | $43.67B | $55.33B | $47.84B | $38.48B |
| Total liabilities | n/a | n/a | $25.42B | $19.20B |
| Shareholders' equity | $24.47B | $25.39B | $22.42B | $10.74B |
| Return on year-end equity | 11.8% | 6.6% | 14.5% | 10.8% |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Boston Scientific Corp | Becton Dickinson & Co | Stryker Corp | Medline Inc. |
|---|---|---|---|---|
| Latest | $20.07B Ended 2025-12-31 | $21.84B Ended 2025-09-30 | $25.12B Ended 2025-12-31 | $28.43B Ended 2025-12-31 |
| 1 year earlier | $16.75B Ended 2024-12-31 | $20.18B Ended 2024-09-30 | $22.59B Ended 2024-12-31 | $25.51B Ended 2024-12-31 |
| 2 years earlier | $14.24B Ended 2023-12-31 | $19.37B Ended 2023-09-30 | $20.50B Ended 2023-12-31 | $23.23B Ended 2023-12-31 |
| 3 years earlier | $12.68B Ended 2022-12-31 | $18.87B Ended 2022-09-30 | $18.45B Ended 2022-12-31 | n/a |
| 4 years earlier | $11.89B Ended 2021-12-31 | $19.13B Ended 2021-09-30 | $17.11B Ended 2021-12-31 | n/a |